Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.
Moving Treatments Earlier in Prostate Cancer Can Prevent Progression, Additional Treatment ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.
Physician-scientists from the Department of Urology at Cedars-Sinai will be attending the American Urological Association (AUA) Annual Meeting May 3-6 in San An
Multiple surveys of patient-reported outcomes from the phase 3 EMBARK trial revealed no meaningful differences in pain progression or urinary symptoms and bowel symptoms or function over 205 weeks of follow-up. Enzalutamide does not worsen health-related quality of life compared with androgen deprivation therapy in patients with high-risk biochemically recurrence nmCSPC.